Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Arcutis Biotherapeutics stock
Learn how to easily invest in Arcutis Biotherapeutics stock.
Arcutis Biotherapeutics Inc is a biotechnology business based in the US. Arcutis Biotherapeutics shares (ARQT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcutis Biotherapeutics employs 143 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Arcutis Biotherapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ARQT – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Arcutis Biotherapeutics stock price (NASDAQ: ARQT)Use our graph to track the performance of ARQT stocks over time.
Arcutis Biotherapeutics shares at a glance
|Latest market close||$15.89|
|52-week range||$14.16 - $38.49|
|50-day moving average||$18.02|
|200-day moving average||$23.12|
|Wall St. target price||$53.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.55|
Buy Arcutis Biotherapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Arcutis Biotherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Arcutis Biotherapeutics price performance over time
|1 week (2022-01-18)||-1.24%|
|1 month (2021-12-23)||-20.95%|
|3 months (2021-10-26)||-26.81%|
|6 months (2021-07-26)||-32.93%|
|1 year (2021-01-26)||-40.06%|
|2 years (2020-01-22)||N/A|
|3 years (2019-01-22)||N/A|
|5 years (2017-01-22)||N/A|
Arcutis Biotherapeutics financials
|Gross profit TTM||$0|
|Return on assets TTM||-36.73%|
|Return on equity TTM||-63.08%|
|Market capitalisation||$799.2 million|
TTM: trailing 12 months
Arcutis Biotherapeutics share dividends
We're not expecting Arcutis Biotherapeutics to pay a dividend over the next 12 months.
Arcutis Biotherapeutics overview
Arcutis Biotherapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.
Arcutis Biotherapeutics in the news
Earnings playbook: A complete guide to this week's reports, including the first of tech
Markets are expected to remain on edge as the Fed meets in the week ahead
Netflix quietly admits streaming competition is eating into growth
Frequently asked questionsWhat percentage of Arcutis Biotherapeutics is owned by insiders or institutions?
Currently 4.958% of Arcutis Biotherapeutics shares are held by insiders and 92.592% by institutions. How many people work for Arcutis Biotherapeutics?
Latest data suggests 143 work at Arcutis Biotherapeutics. When does the fiscal year end for Arcutis Biotherapeutics?
Arcutis Biotherapeutics's fiscal year ends in December. Where is Arcutis Biotherapeutics based?
Arcutis Biotherapeutics's address is: 3027 Townsgate Road, Westlake Village, CA, United States, 91361 What is Arcutis Biotherapeutics's ISIN number?
Arcutis Biotherapeutics's international securities identification number is: US03969K1088 What is Arcutis Biotherapeutics's CUSIP number?
Arcutis Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 03969K108
More guides on Finder
Cardano’s Pavia plot sale shows land rush is on in the metaverse
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart dives deep into the metaverse with crypto and NFTs
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Ask an Expert